Search Within

Min Yuen Teo

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (19)
  2. Journal Article (18)
Groups
  1. Biostatistics Service (37)
  2. Department of Medicine (37)
  3. Epidemiology and Biostatistics (37)
  4. Genitourinary Oncology Service (37)
  5. Solid Tumor Oncology Division (37)
  6. Weinberg Fellows (29)

More Groups

People
  1. Gopakumar Iyer (33)
  2. Jonathan Rosenberg (32)
  3. Irina Ostrovnaya (30)
  4. Dean Bajorin (28)
  5. Samuel Funt (25)
  6. Hikmat Al-Ahmadie (23)

More People

Years
  1. 2024 (7)
  2. 2023 (2)
  3. 2022 (11)
  4. 2021 (4)
  5. 2020 (4)
  6. 2019 (4)

More Years

Publications
  1. Journal of Clinical Oncology (20)
  2. Clinical Genitourinary Cancer (2)
  3. JCO Precision Oncology (2)
  4. Annals of Oncology (1)
  5. Bladder Cancer (1)
  6. British Journal of Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (22)
  2. American Association for Cancer Research (2)
  3. Cell Press (2)
  4. Elsevier Inc. (2)
  5. Nature Publishing Group (2)
  6. Biomed Central Ltd (1)

More Publishers

Results (37)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial
    Meeting Abstract

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H. A.; Quinlan, C.; Teo, M. Y.; Kamradt, J.; Khalil, M. F.; Ostrovnaya, I.; McCoy, A. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Pretreatment eosinophil counts in patients with advanced or metastatic urothelial carcinoma treated with anti-PD-1/PD-L1 checkpoint inhibitors
    Journal Article

    Mota, J. M.; Teo, M. Y.; Whiting, K.; Li, H. A.; Regazzi, A. M.; Lee, C. H.; Funt, S. A.; Bajorin, D.; Ostrovnaya, I.; Iyer, G.; more...
    Journal of Immunotherapy (2021)

    Fulltext@MSK | Save
  • Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma
    Journal Article

    Teo, M. Y.; Al-Ahmadie, H.; Seier, K.; Tully, C.; Regazzi, A. M.; Pietzak, E.; Solit, D. B.; Tickoo, S.; Reuter, V.; Cha, E. K.; more...
    British Journal of Cancer (2021)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
    Journal Article

    Sarfaty, M.; Whiting, K.; Teo, M. Y.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; Jungbluth, A. A.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma
    Journal Article

    Teo, M. Y.; Mota, J. M.; Whiting, K. A.; Li, H. A.; Funt, S. A.; Lee, C. H.; Solit, D. B.; Al-Ahmadie, H.; Milowsky, M. I.; Balar, A. V.; more...
    European Urology (2020)

    Fulltext@MSK | Save
  • Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC)
    Meeting Abstract

    Teo, M. Y.; Whiting, K.; Mota, J. M.; Li, H.; Regazzi, A. M.; Solit, D. B.; Aggen, D. H.; Lee, C. H.; Funt, S. A.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
    Journal Article

    Ged, Y.; Chaim, J. L.; DiNatale, R. G.; Knezevic, A.; Kotecha, R. R.; Carlo, M. I.; Lee, C. H.; Foster, A.; Feldman, D. R.; Teo, M. Y.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract
    Meeting Abstract

    Sarfaty, M.; Ostrovnaya, I.; Teo, M. Y.; Iyer, G.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI)
    Meeting Abstract

    Mota, J. M.; Teo, M. Y.; Whiting, K.; Ostrovnaya, I.; Li, H.; Lee, C. H.; Funt, S. A.; Callahan, M. K.; Iyer, G.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save